Table 1.

ER, PR and HER2 conversion in primary and metastatic sites.

ER, PR, and HER2 status	ER		PR		HER2
	N	%	N	%	N	%
Primary tumor and metastasis
Local and distant metastasis
Primary positive/metastasis positive	186	43.7	95	22.5	57	18.5
Primary positive/metastasis negative	63	14.8	117	27.7	17	5.5
Primary negative/metastasis positive	27	6.3	23	5.5	19	6.1
Primary negative/metastasis negative	150	35.2	187	44.3	216	69.9
Total	426	100.0	422	100.0	309	100.0
Local metastasis
Primary positive/metastasis positive	86	43.4	37	18.9	26	17.0
Primary positive/metastasis negative	19	9.6	54	27.6	7	4.6
Primary negative/metastasis positive	11	5.6	13	6.6	6	3.9
Primary negative/metastasis negative	82	41.4	92	46.9	114	74.5
Total	198	100.0	196	100.0	153	100.0
Distant metastasis
Primary positive/metastasis positive	100	43.9	58	25.7	31	19.9
Primary positive/metastasis negative	44	19.3	63	27.9	10	6.4
Primary negative/metastasis positive	16	7.0	10	4.4	13	8.3
Primary negative/metastasis negative	68	29.8	95	42.0	102	65.4
Total	228	100.0	226	100.0	156	100.0
Multiple metastasis*
Both local and distant metastasis
Metastasis positive/metastasis positive	32	47.1	11	16.2	8	15.7
Metastasis positive/metastasis negative	7	10.3	13	19.1	2	3.9
Metastasis negative/metastasis positive	6	8.8	3	4.4	3	5.9
Metastasis negative/metastasis negative	23	33.8	41	60.3	38	74.5
Total	68	100.0	68	100.0	51	100.0

^*The earliest metastasis and the second metastasis.

ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; PR, progesterone receptor.